Abstract library

8 results for "González".
#191 Immunohistochemical Analysis of Epithelial-Mesenchymal Transition Markers in Neuroendocrine Tumors of the Lung
Introduction: The increased motility and invasiveness of cancer cells in the first phase of metastasis are reminiscent of epithelial–mesenchymal transition (EMT) during embryonic development.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Jose Galván
#710 Characterization of Elderly Patients (≥70 Years) with Neuroendocrine Tumors (NETs)
Introduction: Incidence of NETs increases with age; however, age-specific epidemiologic analyses are lacking.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: María Isabel Sevilla García
Keywords: elderly, NETs
#882 Gene Expression Characterization of Gastroenteropancreatic Neuroendocrine Tumors [GEPNETS: Gastrointestinal and Pancreatic NETs (GINETs and pNETs)] and Their Correlation with Clinical Factors and Tumor Behavior
Introduction: GEP-NETs are a heterogenous group of tumors with different molecular backgrounds and clinical outcome.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: J A Díaz Pérez
#929 Prognostic Role of Smoking in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)
Introduction: Large retrospective series identified several prognostic factors for GEP-NET such as sex, race, age, primary localization, stage or tumor grade. Several studies suggested a prognostic role of smoking in many cancer types. However, no data has been reported in GEP-NET.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Francesc Pons
Authors: Pons F, Mar I, Gallego R, Luque A, ...
#1711 Survival Analysis of Combined Therapy with 177Lu-Octreotate and Somatostatin Analogues in Advanced Metastatic Neuroendocrine Tumours
Introduction: Although somatostatin analogues (SSA) and peptide receptor radionuclide therapy with 177Lu-octreotate (PRRT) are validated therapies in patients with advanced metastatic neuroendocrine tumours, it is still unclear if the combined therapy with PRRT and SSA can provide a prolonged survival compared to patients treated with PRRT alone.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Dr. Anna Yordanova
#1772 Expression of Truncated Functional Subtype 5 Somatostatin Receptor Variant (sst5TMD4) in GEP-NETs and Association with Relevant Pathways Involved in NET Tumorigenesis
Introduction: Sst5TMD4, which is derived from a non-canonical splicing process of sst5 receptor, is overexpressed in several endocrine tumors and associated with a worse prognosis.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr. Angel Diaz Perez
#1906 High Prevalence of the c.1546delC Germline Mutation in MEN1 Pancreatic Neuroendocrine Tumors
Introduction: Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disease predisposing to pancreatic neuroendocrine neoplasms (NENs). Even though its genetics is relatively well known, specific phenotype-genotype correlations remain unproven at present. The Region of Murcia in southeast Spain is one of the areas with the highest incidence of MEN1
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Alberto Carmona-Bayonas
Keywords: MEN1 genetics
#2122 Is the EORTC QLQ-QNET21 Optimal for Patients with Neuroendocrine Tumors?
Introduction: Quality of life (QoL) is important to all cancer patients. The EORTC QLQ-QNET21 is the most commonly used questionnaire in patients with neuroendocrine tumors (NETs).
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: MD Rachel van Leeuwaarde